Alkermes (ALKS) Short term Debt (2011 - 2026)

Alkermes (ALKS) posted quarterly Short term Debt of $26.5 million for Q2 2026, little changed quarter-over-quarter from $26.5 million in Q1 2026.

Alkermes (ALKS) Short term Debt (2011 - 2026) Analysis & Trends

Alkermes (ALKS) has reported Short term Debt for 15 consecutive years, with $26.5 million the latest figure, recorded in Q2 2026.

In Q2 2026, Short term Debt changed N/A year-over-year to $26.5 million; the TTM figure through Jun 2026 stood at $26.5 million (changed N/A YoY), while the FY2023 annual figure was $3.0 million, changed 0.0% from the prior year.
Short term Debt steadied at $26.5 million in Q2 2026 per ALKS's latest filing, from $26.5 million in the prior quarter.
Across five years, Short term Debt topped out at $26.5 million in Q1 2026 and bottomed at $3.0 million in Q1 2022.
Historically, Short term Debt has averaged $6.6 million across 4 years, with a median of $3.0 million in 2022.
On a YoY basis, Short term Debt climbed as much as 0.0% in 2022 and fell as far as 0.0% in 2022.
Alkermes' Short term Debt stood at $3.0 million in 2022, then changed by 0.0% to $3.0 million in 2023, then changed by 0.0% to $3.0 million in 2024, then soared by 783.33% to $26.5 million in 2026.
Business Quant data shows ALKS's Short term Debt at $26.5 million in Q2 2026, $26.5 million in Q1 2026, and $3.0 million in Q3 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.91 Bn	42.95 Bn	-
2	Teva Pharmaceutical Industries	42.98 Bn	39.32 Bn	2.15 Bn
3	Zoetis	31.53 Bn	29.86 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.61 Bn	22.81 Bn	5.10 Bn
5	United Therapeutics	22.16 Bn	19.49 Bn	683.80 Mn
6	Viatris	18.74 Bn	17.85 Bn	1.46 Bn
7	Neurocrine Biosciences	15.51 Bn	15.12 Bn	935.80 Mn
8	Elanco Animal Health	11.76 Bn	11.23 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.12 Bn	9.95 Bn	-
10	Alkermes	8.12 Bn	7.46 Bn	397.90 Mn

Download Data